Mani (7730) Q1 2025 earnings summary

Executive summary

• Management is accelerating growth plans, maintaining core values while adopting a proactive, challenge-oriented approach to achieve key sales and income targets ahead of schedule.

• Revenue increased 7.6% year-over-year to ¥7,655 million, driven by strong Surgical and Eyeless Needle segments, while Dental segment sales declined, mainly in China.

• Net income rose 1.6% year-over-year to ¥1,598 million, despite a 5.2% decrease in operating income due to higher personnel and bonus costs.

• Strategic focus includes global expansion, new product development, and operational excellence, with new sales subsidiary established in the US and launch of JIZAI 020 04 NiTi rotary file.

• Sales growth was robust in Europe and North America, but Asia, particularly China, saw declines.

Financial highlights

• Net sales for FY2025 are expected to reach JPY 30.2 billion, achieving the five-year plan target one year early.

• Operating income is slightly below the JPY 10 billion target but is on track for early achievement.

• Net income forecast for FY2025: ¥6,350 million; 1Q progress rate: 25.2%.

• Ambitious targets for FY2029: JPY 50 billion in net sales, JPY 15 billion in operating income, and 16% ROE.

• Cost of sales ratio improved to 34.7% from 37.5% year-over-year; gross margin improved to 65.3%.

Outlook and guidance

• Net sales target of JPY 50 billion and operating income of JPY 15 billion by FY2029, two years ahead of the original plan.

• Full-year net sales forecast unchanged at ¥30,200 million, up 6.1% year-over-year.

• CAGR of around 12% is targeted, with a focus on both existing and new products.

• Next medium-term management plan to be announced around July–September 2025.

• Management notes forecasts are subject to risks and uncertainties.